Skip to content

Oruka Therapeutics

US · ORKA #2003 by market cap Listed 1970
95.81 -1.76 -1.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Company notice
    Oakridge International Ltd: KS Orka Completes Acquisition of Sokoria Geothermal Project
    N/A · 2017/1/16
  • Rating change
    UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/9/2
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Fractyl Health, Inc. (GUTS) and Oruka Therapeutics (ORKA)
    TipRanks · 2026/9/2
  • Company notice
    Kaishan Co., Ltd.: The holding company KS Orka Renewables Pte Ltd and PT Optima Nusantara Energi's announcement on joint development of the Simbolon-Samosir geothermal project
    SZSI · 2018/3/19
  • Company notice
    Kaishan Co., Ltd.: Announcement on the signing of a letter of intent for a joint venture between its wholly-owned subsidiary KS ORKA and a Hungarian partner
    SZSI · 2025/11/27
  • Rating change
    Wedbush Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $165
    Market Newswire · 2026/9/24
  • Rating change
    Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $160
    Market Newswire · 2026/9/21
  • A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $180
    Market Newswire · 2026/11/11
  • Piper Sandler Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $180
    Market Newswire · 2026/10/7
  • A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $160
    Market Newswire · 2026/11/10
  • Leerink Partners Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
    Market Newswire · 2026/10/28
  • BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $151
    Market Newswire · 2026/10/19
  • Rating change
    H.C. Wainwright Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $120
    Market Newswire · 2026/10/27
  • Rating change
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $120 to $175
    Market Newswire · 2026/9/24
  • Rating change
    LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $175
    Market Newswire · 2026/9/9
  • Company notice
    Kaishan Co., Ltd.: Announcement on KS ORKA Hungary\'s acquisition of exclusive geothermal exploration rights in Hungary
    SZSI · 2025/4/10
  • Rating change
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $133 to $180
    Market Newswire · 2026/8/12
  • Company notice
    Oakridge International Ltd: KS Orka to Acquire Sokoria Geothermal Project
    N/A · 2016/8/2
  • Rating change
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $105 to $160
    Market Newswire · 2026/10/27
  • Rating change
    TD Cowen Maintains Oruka Therapeutics(ORKA.US) With Buy Rating
    Market Newswire · 2026/8/26
  • Rating change
    LifeSci Capital Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $125
    Market Newswire · 2026/8/1
  • Rating change
    A Quick Look at Today's Ratings for Oruka Therapeutics(ORKA.US), With a Forecast Between $151 to $200
    Market Newswire · 2026/8/11
  • Rating change
    Stifel Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $150
    Market Newswire · 2026/6/29
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
    TipRanks · 2026/7/14
  • Rating change
    UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/6/2

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Oruka Therapeutics discussion 0 comments

Add a comment